Benign prostatic hyperplasia. Enlarged prostate
Conditions
Interventions
Intervention 1: Intervention group: Treated with tadalafil (PROCIAL brand) 5 mg daily for one month prior to surgery. Intervention 2: Control group: Treated with a placebo identical to tadalafil, one
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with benign prostate enlargement (BPE) who underwent transurethral resection of prostate (TURP) surgery at Khorshid and Alzahra centers in Isfahan during the period of September 2025 to September 2026.
Exclusion criteria
Exclusion criteria: Patients with BPE treated by any method other than transurethral resection of prostate (TURP) Patients with BPE who are on medication Patients with BPE who have a coagulation disorder Patients with BPE who have neurological disorders Patients with BPE who have contraindications to tadalafil Patients with BPE who have been treated with alpha-blockers and 5-alpha-reductase inhibitors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in hemoglobin and hematocrit after surgery. Timepoint: Hemoglobin and hematocrit measurements before and after surgery. Method of measurement: Automated hematology analyzer. | — |
Secondary
| Measure | Time frame |
|---|---|
| Prostate volume. Timepoint: One month Before surgery. Method of measurement: sonography.;Prostate specific antigen level. Timepoint: One month before surgery. Method of measurement: immunoassay analyzer.;Micro vessel density. Timepoint: During surgery. Method of measurement: immunohistochemical staining. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMoein Bighamian
Esfahan University of Medical Sciences
Outcome results
None listed